A Double-Blind (Sponsor Unblinded), Randomized, Placebo-Controlled, Continuation Single and Repeated Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2838232 With Ritonavir, in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 20 Jan 2017
At a glance
- Drugs GSK 2838232 (Primary) ; Ritonavir
- Indications HIV infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GlaxoSmithKline
- 16 Jan 2017 Status changed from active, no longer recruiting to completed.
- 28 Nov 2016 Status changed from recruiting to active, no longer recruiting.
- 08 Nov 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Dec 2016.